Genocea Biosciences Inc (GNCAQ)

[NY1972]

Patients with high-risk solid tumors reported to express one or more target tumor antigens—WT1, PRAME, and/or survivin

Patients who were treated on this study had no prior lymphodepletion, which may explain the lack of cytokine release and elevation in Th1 cytokines associated with TAA-T infusion, despite evidence of T-cell expansion postinfusion. Surge of IL-8, a known marker of tumor progression, was observed in some patients,48 which correlated with disease progression in three patients. Conversely, IL-8 levels decreased after TAA-T infusion in three responding patients, suggesting tumor control and in vivo efficacy.

https://ascopubs.org/doi/full/10.1200/JCO.19.00177